All In Biotech

Drug Trial Radar · NCT07783542

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Oct 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • ORKA-002Drug

    ORKA-002 administered by subcutaneous (SC) injection

  • PlaceboOther

    Placebo administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving HiSCR75 at Week 16Time frame: Week 16

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Birmingham, Alabama · Recruiting

  • Oruka Therapeutics Investigative Site

    Fountain Valley, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Los Angeles, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Cromwell, Connecticut · Recruiting

  • Oruka Therapeutics Investigative Site

    Sandy Springs, Georgia · Recruiting

  • Oruka Therapeutics Investigative Site

    Chicago, Illinois · Recruiting

  • Oruka Therapeutics Investigative Site

    Plainfield, Indiana · Recruiting

  • Oruka Therapeutics Investigative Site

    Baton Rouge, Louisiana · Recruiting

  • Oruka Therapeutics Investigative Site

    New Orleans, Louisiana · Recruiting

  • Oruka Therapeutics Investigative Site

    Canton, Michigan · Recruiting

  • Oruka Therapeutics Investigative Site

    New Brighton, Minnesota · Recruiting

  • Oruka Therapeutics Investigative Site

    St Louis, Missouri · Recruiting

  • Oruka Therapeutics Investigative Site

    Omaha, Nebraska · Recruiting

  • Oruka Therapeutics Investigative Site

    New York, New York · Recruiting

  • Oruka Therapeutics Investigative Site

    Chapel Hill, North Carolina · Recruiting

  • Oruka Therapeutics Investigative Site

    Portland, Oregon · Recruiting

  • Oruka Therapeutics Investigative Site

    Smyrna, Tennessee · Recruiting

  • Oruka Therapeutics Investigative Site

    Dallas, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    Missouri City, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    San Antonio, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    Surrey, British Colombia, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Barrie, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    London, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Peterborough, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Waterloo, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.